Abstract:<h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">BACKGROUND</h3><p><strong>:</strong> Visceral obesity and fatty liver are prevalent in postmenopausal women. The stilbene-rich extract of <em>Cajanus cajan</em> (L.) Millsp. has been reported to prevent ovariectomy-induced and diet-induced weight gain in animal models, and stilbenoids from <em>C. cajan</em> are thought to have the potential to prevent postmenopausal obesity and fatty liver.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">PURPOSE</h3><p><strong>:</strong> Cajanolactone A (CLA) is the main stilbenoid from <em>C. cajan</em> with osteoblastogenic promoting activity. This study investigated the potential of CLA to prevent postmenopausal obesity and fatty liver. Underlying mechanisms were also investigated.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">METHOD</h3><p><strong>:</strong> Ovariectomized C57BL/6 mice fed a regular diet were used as mimics of postmenopausal women and given 10, 20, or 40 mg/kg/d of CLA, 0.1 mg/kg/d of estradiol valerate (EV, positive control), or vehicle (OVX) orally for 16 weeks. Mice of the same age subjected to a sham operation were used as control (Sham). Body weights were recorded every 2 weeks for 16 weeks. Body compositions were analyzed via micro-CT. Serum levels of lipids, adipocytokines and aminotransferases were measured using the relevant kits. mRNA levels of genes of interest were detected by RT-qPCR. Proteomic study of perigonadal white adipose tissue (pWAT) was performed using tandem-mass-tags-based proteomic technology combined with Parallel-Reaction-Monitoring (PRM) validation.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">RESULTS</h3><p><strong>:</strong> CLA showed potential equivalent to that of EV to prevent ovariectomy-induced overweight, obesity, dyslipidemia, liver steatosis and liver dysfunction, but did not prevent uterine atrophy. In the liver, CLA significantly inhibited ovariectomy-induced upregulation in expression of lipogenic genes <em>SREBP-1c</em> and <em>ChREBP</em>, and stimulated the mRNA expression of apolipoprotein B gene <em>ApoB</em>. In pWAT, CLA reversed, or partially reversed ovariectomy-induced downregulation in the expression of a number of metabolism- and mitochondrial-function-related proteins, including Ndufa3, Pcx, Pdhb, Acly, Acaca, Aldh2, Aacs and Echs1. In addition, ovariectomy-inhibited mRNA expression of <em>Pdhb, Aacs, Acsm5, Echs1,</em> and <em>Aldh2</em> genes in pWAT was also reversed.</p><h3 class="u-h4 u-margin-m-top u-margin-xs-bottom">CONCLUSION</h3><p><strong>:</strong> CLA was demonstrated to be a potential non-estrogen-like drug candidate for prevention of postmenopausal obesity and fatty liver. The underlying mechanism might involve the inhibition of lipogenesis and promotion of triglycerides output in the liver, and the promotion of metabolism and mitochondrial functions of visceral white adipose tissue.</p>

Targeted inhibition of PPAR α ameliorates CLA ‐induced hypercholesterolemia via hepatic cholesterol biosynthesis reprogramming

Co‐option of PPARα in the regulation of lipogenesis and fatty acid oxidation in CLA‐induced hepatic steatosis

Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor α agonists

Modulation Of Peroxisome Proliferator-Activated Receptor Gamma (Ppar Gamma) By Conjugated Fatty Acid In Obesity And Inflammatory Bowel Disease

Conjugated Linoleic Acid Ameliorates Hepatic Steatosis by Modulating Intestinal Permeability and Gut Microbiota in Ob/ob Mice

Conjugated linoleic acid (CLA) reduces intestinal fatty acid uptake and chylomicron formation in HFD-fed mice associated with the inhibition of DHHC7-mediated CD36 palmitoylation and the downstream ERK pathway

Mixed conjugated linoleic acid sex-dependently reverses high-fat diet-induced insulin resistance via the gut-adipose axis

Conjugated Linoleic Acid Ameliorates High Fat-Induced Insulin Resistance via Regulating Gut Microbiota–Host Metabolic and Immunomodulatory Interactions

The Effects of New Selective PPARα Agonist CP775146 on Systematic Lipid Metabolism in Obese Mice and Its Potential Mechanism.

Effect of Conjugated Linoleic Acid on Inhibition of Prolyl Hydroxylase 1 in Hearts of Mice

Combination of Fucoxanthin and Conjugated Linoleic Acid Attenuates Body Weight Gain and Improves Lipid Metabolism in High-Fat Diet-Induced Obese Rats.

Conjugated linoleic acid (CLA) reduces HFD‐induced obesity by enhancing BAT thermogenesis and iWAT browning via the CD36–AMPK pathway

10E,12Z-conjugated linoleic acid impairs adipocyte triglyceride storage by enhancing fatty acid oxidation, lipolysis, and mitochondrial reactive oxygen species

Hepatic Reduction in Cholesterol 25-Hydroxylase Aggravates Diet-induced Steatosis

Cajanolactone A, a stilbenoid from Cajanus cajan, inhibits energy intake and lipid synthesis/storage, and promotes energy expenditure in ovariectomized mice

Conjugated linoleic acids inhibit lipid deposition in subcutaneous adipose tissue and alter lipid profiles in serum of pigs

Clitorin ameliorates western diet-induced hepatic steatosis by regulating lipogenesis and fatty acid oxidation in vivo and in vitro

10,12-Conjugated linoleic acid supplementation improves HDL composition and function in mice

Stimulation of cardiac cardiolipin biosynthesis by PPARα activation

Identification of Novel Human High-Density Lipoprotein Receptor Up-regulators Using a Cell-Based High-Throughput Screening Assay

Cajanolactone A, a stilbenoid from cajanus cajan, prevents ovariectomy-induced obesity and liver steatosis in mice fed a regular diet